Guy Villax
Hovione
Board Member
Guy Villax, Portuguese, is a non-executive member of the Hovione Holding AG board, of the supervisory Board of EIT Health, of the advisory board of Phlow Corp., and of the sustainability advisory board of AGEAS Portugal. He is President of the Health Cluster Portugal and member of the Portuguese National Council on Science, Technology, and Innovation.
Guy was previously Hovione's Chief Executive Officer (from 1997 to 2022), and worked at Price Waterhouse in London and Hovione in Asia.
Guy Villax was on the EFCG’s Board (European Fine Chemicals group, a CEFIC committee in Brussels) from 2004 to 2016. Over this period Guy was involved in many EFCG advocacy activities to express the voice of the API industry in a wide range of legislative matters.
He testified in 2007 before a US Congress sub-committee on the risks of globalization of the pharma supply chain, falsified medicines and the weak oversight of regulators over API producers located abroad – this took place 2 months before the counterfeit heparin tragedy that killed over one hundred patients.
Guy was part of the EFCG Team that represented the API industry’s views during the legislative process that led to the European Parliament voting the Directive on Falsified Medicines.
He represented the EU API industry in the negotiations with the US FDA during 2011 that resulted in the Generic Drugs User Fee Act (GDUFA). This legislation led to faster approval of ANDAs (market authorizations for the US generics market) and a sharp increase in FDA inspections in India and China and the creation of FDA offices in these countries.
Guy Villax was a board member of Rx-360 from 2010 to 2017, having been Chair in 2016/17. This consortium brings together companies in the pharmaceutical value chain, whose mission is to fight counterfeit medicines.
Guy Villax has a degree in Management from Buckingham University, he is fluent in English, French, Portuguese, Italian and Spanish.
Guy was previously Hovione's Chief Executive Officer (from 1997 to 2022), and worked at Price Waterhouse in London and Hovione in Asia.
Guy Villax was on the EFCG’s Board (European Fine Chemicals group, a CEFIC committee in Brussels) from 2004 to 2016. Over this period Guy was involved in many EFCG advocacy activities to express the voice of the API industry in a wide range of legislative matters.
He testified in 2007 before a US Congress sub-committee on the risks of globalization of the pharma supply chain, falsified medicines and the weak oversight of regulators over API producers located abroad – this took place 2 months before the counterfeit heparin tragedy that killed over one hundred patients.
Guy was part of the EFCG Team that represented the API industry’s views during the legislative process that led to the European Parliament voting the Directive on Falsified Medicines.
He represented the EU API industry in the negotiations with the US FDA during 2011 that resulted in the Generic Drugs User Fee Act (GDUFA). This legislation led to faster approval of ANDAs (market authorizations for the US generics market) and a sharp increase in FDA inspections in India and China and the creation of FDA offices in these countries.
Guy Villax was a board member of Rx-360 from 2010 to 2017, having been Chair in 2016/17. This consortium brings together companies in the pharmaceutical value chain, whose mission is to fight counterfeit medicines.
Guy Villax has a degree in Management from Buckingham University, he is fluent in English, French, Portuguese, Italian and Spanish.